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New NICE Guideline on the Treatment of Hypertension
TOMMY TSANG CHEUNG AND BERNARD MAN-YUNG CHEUNG
From Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong,
Hong Kong
CHEUNG AND CHEUNG: New NICE guideline on the treatment of Hypertension. The British guidelines on
the management of primary hypertension, developed by the National Institute for Clinical Excellence (NICE),
have just been published in August 2011. There are several significant changes in the diagnosis and the treatment
for primary hypertension in adults. Ambulatory blood pressure measurement should be regarded as the new
gold standard in the diagnosis. Home blood pressure monitoring is also useful for the diagnosis and monitoring
of hypertension. Because of the results of the Anglo-Scandinavian Cardiac Outcomes Trial study, calcium channel
blockers (CCB) and blockers of the renin-angiotensin system have surpassed diuretics and beta-blockers as
first line options. Patients younger than 55 should receive an ACE inhibitor, or an angiotensin receptor blocker
if the former is not tolerated. Older patients should be started on a CCB. A thiazide diuretic can be used as an
adjunct to the first line treatment. Chorthalidone and indapamide are preferred as they showed favorable outcomes
in large clinical trials. Treatment with these three drug classes should be sufficient in the majority of patients,
but if triple therapy is still insufficient, referral to a hypertension specialist is recommended. Further diuretic
therapy with spironolactone can be used as the fourth line treatment. Some aspects of the new guideline are
controversial, such as the practical difficulties of using ambulatory blood pressure monitoring in family practice,
and the arbitrary blood pressure cutoff levels. Many doctors also believe that control of blood pressure is best
achieved using a wider range of drugs to suit the individual patient. (J HK Coll Cardiol 2012;20:15-20)
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Introduction
In Hong Kong, the prevalence of hypertension
has been increasing among young and middle-aged
men, and is approaching 50% among the elderly.
Hypertension has been shown to increase the risk of
stroke and myocardial infarction, and increase the
incidence of heart failure and the progression of chronic
kidney disease. The key to reducing cardiovascular
complications in patients with hypertension is early
detection and effective treatment leading to good
blood pressure control. Therefore, guidelines on the
management of hypertension are developed. The British
guidelines developed by the National Institute for
Clinical Excellence (NICE) have just been published
in August 2011.1 The guidelines cover the new methods
of blood pressure measurement for the diagnosis of
hypertension; blood pressure thresholds for intervention
with drug therapy and blood pressure targets for
treatment. Most importantly, there are significant
changes in the recommendations for the treatment of
hypertension.

NICE Methodology
The NICE guidelines on hypertension is highly
evidence based and it incorporates cost-effectiveness
considerations. Compared to many other consensus
guidelines, it is less dependent on expert opinion, but it
also includes a diverse range of opinions, including nonspecialists, non-clinicians, and the pharmaceutical
industry. These stakeholders were engaged in the
guideline development process.

Blood Pressure Measurement for the
Diagnosis of Hypertension
Ambulatory blood pressure is now the new gold
standard in the diagnosis of hypertension. If the clinic
blood pressure is 140/90 mmHg or higher, it is
recommended to offer patients ambulatory blood
pressure monitoring to confirm the diagnosis, unless at
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presentation, the patient already has severe
hypertension. It is measured twice every hour during
the usual waking hours of the individual. This is valuable
not only in people with white coat hypertension, but
also in people whose ambulatory blood pressures are
higher than blood pressure readings in the clinic. This
entity is called reverse white coat hypertension or masked
hypertension.2 In this scenario, traditional blood pressure
measurements fail to identify patients at risk. As a result,
patients with masked hypertension have a higher
cardiovascular risk due to under-treatment. Due to the
need to diagnose white coat and masked hypertension,
the new guidelines recommend ambulatory or home
blood pressure monitoring.
However, ambulatory blood pressure monitoring
is not always available and its repeated use for
monitoring purposes is inconvenient. Home blood
pressure monitoring is now also recognized to be useful
in the diagnosis of hypertension and the monitoring of
blood pressure.3 Patients are recommended to measure
the blood pressure twice daily, each recording with two
consecutive measurements of at least 1 minute apart,
for at least four days a week. Home blood pressure
monitoring is widely promoted as the machines are
inexpensive and readily available. Therefore, it
encourages patients to be involved in their own care
and they can provide more comprehensive readings
spreading over a long period of time. However, they
cannot be calibrated as easily as the machines used in
clinics, and the accuracy of home readings depends on
adequate resting before measurement, proper
application of cuff and correct operation of the machine.
Significant measurement errors may occur in patients
with arrhythmias such as atrial fibrillation. There is also
a potential concern that patients may adjust their
medications according to the home blood pressure
readings, which should be discouraged in most
circumstances.
Ambulatory blood pressure monitoring and home
blood pressure monitoring pose an enormous challenge
to family practices where there are large numbers of
patients with hypertension. The new NICE guideline
has not set out recommendations on what to do if neither
is available. A practical compromise is to carry out
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multiple measurements of blood pressure, preferably
on separate occasions, in well-rested patients by a
trained staff such as the practice nurse.

Blood Pressure Threshold for Intervention
In the new guidelines, patients who present with more
severe hypertension, e.g. stage 2 hypertension (clinic
blood pressure ≥160/100 mmHg or ambulatory/home
blood pressure ≥150/95 mmHg) should be treated
promptly with anti-hypertensive medications to achieve

satisfactory blood pressure control. Patients aged under
80 years with stage 1 hypertension and evidence of target
organ damage such as left ventricular hypertrophy,
albuminuria, hypertensive retinopathy; established
cardiovascular disease, renal disease, diabetes or those
whose 10-year cardiovascular risk exceeds 20% should
also receive drug treatment early. If the risk is not over
20%, then stage 1 hypertension can be treated less
aggressively with lifestyle changes, patient education
and periodic follow-up and monitoring. The
recommended care pathway is set out in Figure 1. It
should be noted that ambulatory blood pressure plays a

Figure 1. Care pathway for hypertension.
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key role in this algorithm. It is believed that ambulatory
blood pressures are more accurate and reflect prognosis
better, so that there should be less overtreatment (white
coat hypertension) and undertreatment (masked
hypertension).

Target Blood Pressure for Treatment
Clinic blood pressure measurements remain as
the most useful measurement for monitoring the
response to treatment. The target blood pressure for
those younger than 80 years old is defined as lower than
140/90 mmHg. If the 'white coat effect' is present, home
blood pressure monitoring can be used with a target
average blood pressure of 135/85 mmHg.
The new guidelines set a lower clinic blood
pressure target for people aged 80 and over i.e.
150/90 mmHg based on the HYpertension in the Very
Elderly Trial (HYVET).4 For ambulatory and home
blood pressure monitoring, the target of below 145/85
mmHg is recommended. Setting a higher target is based
on the rationale that elderly often have a wide pulse
pressure, such that if the systolic blood pressure is
brought below 140 mmHg, the diastolic blood pressure
can be considerably lower than 90 mmHg. Moreover,
elderly patients often take multiple drugs, which would
lead to considerable side effects and potential noncompliance to the drug treatments.

(Figure 2). Diuretics are now a second line agent and
they could offer an alternative for patients who cannot
tolerate calcium channel blockers.
Calcium channel blockers (CCB) and blockers
of the renin-angiotensin system have surpassed diuretics
and beta-blockers as first line drugs because of the
results of the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT) study,5 which showed that those newer
agents were better than the older agents in terms of
cardiovascular outcomes. Moreover, in ASCOT and in
the relevant meta-analyses, ARB and ACEI were
associated with a decrease in incidence of new onset
diabetes whereas diuretics and beta-blockers were
associated with an increase in the incidence.6

Treatment Strategy for Hypertension
In the new guidelines, there are important changes
to the recommended first line treatment. Patients
under the age of 55 are recommended to receive an
angiotensin-converting enzyme inhibitor or a 'low-cost'
angiotensin receptor blocker first. The combination of
an angiotensin converting enzyme inhibitor with an
angiotensin receptor blocker is generally not
recommended for the indication of treatment of
hypertension. For patients aged 55 or older, a calcium
channel blocker is the first drug to be used. Patient aged
80 and over should be offered the same anti-hypertensive
treatment taken into account of any co-morbidities
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A - Angiotensin converting enzyme inhibitor or
Angiotensin receptor blocker
C - Calcium channel blocker
D - Thiazide diuretics
Figure 2. Summary of anti-hypertensive drug treatment.
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If the blood pressure is not controlled by calcium
channel blocker or blocker of the renin-angiotensin
system alone, combination of both drugs is
recommended. For those who cannot tolerate calcium
channel blockers or with evidence of heart failure,
thiazide diuretics are the appropriate alternative.
Interestingly, chorthalidone and indapamide are
the recommended thiazide diuretic as they showed
favorable outcomes in large clinical trials, such as
Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT)7 and HYVET.
Patients can continue the use of bendroflumethiazide
or hydrochlorothiazide if they are already taking them
with satisfactory control of blood pressure.
Treatment with these three drug classes should
be sufficient in the majority of patients, but if triple
therapy is still insufficient, the patient is deemed to have
resistant hypertension and referral to a hypertension
specialist is recommended. Alpha-blockers were found
to be inferior in ALLHAT, in which treatment with an
alpha-blocker was associated with an increased risk of
heart failure. Beta-blockers were already relegated to
fourth line treatment in the previous NICE guidelines,
because they control blood pressure poorly in the elderly
and tend to cause type 2 diabetes.
Although spironolactone is useful for resistant
hypertension, it may increase the risk of hyperkalaemia,
especially in patients with reduced glomerular filtration
rate. In those high risk patients, higher dose of a thiazide
diuretic should be considered. If further diuretic therapy
for resistant hypertension is not tolerated, or is
contraindicated or ineffective, alpha or beta blocker can
be used as the ultimate options. Spironolactone has been
found to cause cancer in rodents. The uncertain
carcinogenic risk may pose a dilemma for patients with
hypertension who usually have a good life expectancy.

Limitation of the New NICE Guidelines
The new UK guidelines, based on the best
available current evidence, may be criticized for the
heavy reliance on large scale randomized controlled
trials. Therefore, newer drugs tend to be recommended
while older drugs may be disadvantaged due to the
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lack of new evidence. Similarly, lifestyle measure
and population measures have not been emphasized
because of the paucity of randomized controlled trials
showing improvements in hard endpoints. A set of
guidelines based on clinical trial evidence is therefore
limited by the availability of evidence. Brown et al
have set out the gaps in evidence-based treatment of
hypertension.8
The European guidelines on hypertension
management take the view that the differences among
classes of antihypertensive drugs in terms of
cardiovascular outcome are minimal, and so control
of blood pressure should be of paramount importance,
using the whole range of drug classes if necessary.9
Indeed, there are hypertension experts who think
that beta-blockers are under-valued in the NICE
guidelines.10
In the new guidelines, special groups such as
secondary hypertension, diabetic, pregnant or paediatric
patients are not covered. Other than those patients, the
levels of office, ambulatory or home blood pressures
chosen for the diagnosis of hypertension and target
blood pressures are arbitrary, because the relationship
between blood pressure and cardiovascular risk
is continuous. Treatment decisions should therefore
not be based on blood pressure levels alone, a
comprehensive assessment of risks and benefits should
also be included.

Conclusions
Hypertension is more prevalent in the elderly and
because of aging of the Hong Kong population, the
prevalence of hypertension will continue to rise.
Therefore, improvements in diagnosing, treating and
controlling hypertension are badly needed. Lifestyle
modifications and promotion of healthy diet should
be started early in life. For those who have already
developed hypertension, early diagnosis and treatment
are crucial. No single anti-hypertensive drug is ideal
for the treatment of hypertension; the majority of
patients require combination therapy. The new NICE
guidelines help us optimize treatment strategy based
on the best available evidence.
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